bpc-157 human clinical trials rct BPC-157: What the Science Actually Says BPC-157: Dosage, Benefits, FDA Status
Description
Tang JJ, Podratz JL, Lange M, Scrable HJ, Jang MH, Windebank AJ
10.1016/j.pnmrs.2016.08.001 Prog
Occasional mild fatigue may occur early in treatment but usually improves with continued use
160 These results indicated that LMP-1 has an anti-inflammatory effect against TNF- to maintain IVD possibly via ERK1/2 activation and NF-B inhibition
